Herzog Charles

Charles A. Herzog, MD, FACC, FAHA

Commitment to Patient-Centered Care

“My entire professional career has been devoted to improving the health and welfare of patients with heart disease and chronic kidney disease. My clinical work at Hennepin Healthcare, research activities, and efforts with international patient advocacy groups and foundations have all focused on patients with heart disease and kidney disease.”

Clinical Expertise

Dr. Herzog is an internationally recognized authority on heart disease in patients with kidney disease. He is also an authority on echocardiography, with a special interest in stress echocardiography and echo contrast safety. He has personally interpreted more than 51,000 echocardiograms in the past 30 years.


  • Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339:713-718.
  • Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805.
  • Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation. 2007 Sep 25;116(13):1465-1472.
  • Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA. 2008 May 7;299(17):2023-2025.
  • Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients following surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation. 2013 127(18):1861-1869. PMC3767120.

Medical School

  • University of Rochester, Rochester, NY, USA


  • Internal Medicine, University of Minnesota, Minneapolis, MN, USA


  • Cardiology, University of Minnesota, Minneapolis, MN, USA

Media, Newsletters and Videos

The following articles, authored by Dr. Herzog, can be found on thewww.uptodate.comwebsite. Note that a subscription is required.

Professional Affiliations

  • Fellow of the American College of Cardiology
  • Fellow of the American Heart Association
  • Member, American Society of Nephrology
  • Member, International Society of Nephrology


  • Board Certified in Internal Medicine
  • Board Certified in Cardiovascular Disease
  • Professor of Medicine, University of Minnesota


“I have been a cardiologist at Hennepin Healthcare in Minneapolis, consultant to the HCMC ESRD program (dialysis and renal transplant), and University of Minnesota faculty member for 32 years. I founded the program in interventional cardiology at Hennepin Healthcare and served as the cardiac catheterization laboratory director from 1985 to 1991 and as the cardiac ultrasound laboratory director from 1997 through 2012. I was an investigator at the United States Renal Data System (USRDS) Coordinating Center and director of the USRDS Cardiovascular Special Studies Center from 1999-2014. I participated in the development of the National Kidney Foundation’s K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients and the workgroup for the KDIGO Clinical Practice Guidelines on Acute Kidney Injury, helped plan the American Heart Association Cardio-renal Connection Symposium (2010) and co-chaired the 2010 KDIGO Controversies Conference, “Cardiovascular Disease in CKD: What is it and What Can We Do About It?” In the past year, I have participated in the KDIGO Diabetes Controversies Conference (Vancouver), and the KDIGO workgroup for updating the clinical practice guidelines in metabolic bone disease (Baltimore). In 2014, I became the chair of the renal committee of the ISCHEMIA-CKD Trial (ClinicalTrials.gov identifier: NCT01985360), an international NHLBI/NIH-sponsored clinical trial comparing a conservative to an invasive strategy in the treatment of stable ischemic heart disease in patients with severe chronic kidney disease (CKD), including dialysis. I am the Co-PI for the recently initiated WED-HED (Wearable Cardioverter Defibrillator in Hemodialysis Patients) Study (ClinicalTrials.gov identifier: NCT02481206), a randomized clinical trial testing the efficacy of wearable defibrillators for the prevention of sudden cardiac death in incident hemodialysis patients. This ambitious trial, which will enroll up to 2,600 incident hemodialysis patients in up to 200 clinical sites, is the first major attempt to prevent the occurrence of sudden cardiac death in hemodialysis patients using defibrillators. I have authored or co-authored more than 200 published papers, reviews, and editorials and 230 abstracts I have served on the Editorial Boards of the American Heart Journal, the Journal of Nephrology, Clinical Journal of the American Society of Nephrology, and liaison editor for Nephrology, Dialysis and Transplantation.”